Ophthalmic formulation for the prevention and treatment of ocular conditions
An eye disease and preparation technology, applied in the treatment of eye diseases and other adverse eye diseases, in the field of eye disorders, and can solve problems such as traumatic risks of surgical therapy
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0079] An eye drop of the present invention, formulation 1, was prepared as follows: high-purity deionized water (DI) (500 ml) was filtered through a 0.2 micron filter. MSM (27 g), EDTA (13 g) and L-carnosine (5 g) were added to filtered deionized water and mixed until visually clear, indicating dissolution. The mixture was poured into 10ml bottles, each fitted with a dropper cap. Calculated by weight percentage, the eye drops contain the following components:
[0080] Purified deionized water 91.74wt.%
[0081] MSM 4.95wt.%
[0082] Disodium EDTA 2.39wt.%
[0083] L-Carnosine 0.92wt.%.
Embodiment 2
[0085] The therapeutic effect of Formulation 1 was evaluated by four subjects, males aged 52 to 84, regardless of race. Subject 1 was in his fifties with no vision problems or detectable ocular abnormalities. Subjects 2 and 3 were in their fifties with prominent corneal senile rings in both eyes, but no other adverse ocular pathology (senile rings are generally considered a cosmetic defect). Subject 4 was in his octogenarians, suffered from cataracts and Salzmann's tumor, and reported extreme photophobia and glare problems. Subject had difficulty reading newspapers, reading books, and viewing information on computer screens due to glare and reduced clarity of vision.
[0086] All subjects were administered the formulation, one drop (approximately 0.04 mL) per eye, 2 to 4 times daily, for more than 12 months. During and after this 12-month period, all subjects were examined by an ophthalmologist. No side effects other than mild irritation upon application of the formulation ...
Embodiment 3
[0096] The second eye drop preparation of the present invention, preparation 2 is prepared by the following method:
[0097] High-purity deionized (DI) water (500 mL) was filtered through a 0.2 micron filter. MSM (13.5 g), EDTA (6.5 g) and L-carnosine (5.0 g) were added to filtered DI water and mixed until visibly clear, indicating dissolution. The mixture was poured into a 10 mL vial with a drop cap. Based on weight percent, the eye drop composition has the following components:
[0098] Purified deionized water 95.24wt.%
[0099] MSM 2.57wt.%
[0100] Disodium EDTA 1.24wt.%
[0101] L-Carnosine 0.95wt.%.
PUM
| Property | Measurement | Unit |
|---|---|---|
| melting point | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More